PROSTATIC NEOPLASMS

This study compares two common radiation therapy schedules for men with prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. The goal is to see which schedule better controls the cancer and causes fewer side effects over 5 to 10 years. About 400 men with early-stage…

This study tests whether adding the drug apalutamide to standard radiation and hormone therapy can delay cancer spread or death in men with high-risk prostate cancer that has not yet spread. About 692 participants are involved. The approach uses advanced imaging (PSMA-PET) to tra…

This study tests a new treatment called 177Lu-PSMA-617, a type of targeted radiation, in 469 men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if it delays cancer growth or improves survival compared to switching to an…

This study provides early access to apalutamide for men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal is to gather more safety information while offering the drug before it becomes widely available. Participants mus…

This study tests whether adding the drug apalutamide to standard hormone therapy and radiation can delay the spread of prostate cancer in people with high-risk, localized disease. About 1,500 participants will receive either the drug combination or a placebo. The main goal is to …

This study tested whether adding the drug apalutamide to a standard two-drug therapy (abiraterone and prednisone) could help men with a certain type of advanced prostate cancer that had stopped responding to hormone therapy but had not yet received chemotherapy. About 982 men too…

This study looks at whether a 16-week home-based exercise program can slow prostate cancer growth in Black men who are monitoring their cancer without immediate treatment. The program involves high-intensity interval training (HIIT) done virtually with a coach. Researchers will m…

This early-phase study tested the drug apalutamide in 19 Chinese men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to see how the drug moves through the body and check for side effects. Researchers also looked at changes in PSA levels, a marker of pro…

This study looked at how two prostate cancer drugs (JNJ-56021927 and abiraterone acetate) interact in the body and whether combining them is safe. It involved 57 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. …

This early-stage study tests a new drug called JNJ-78278343 for men with advanced prostate cancer that has spread. The drug works by redirecting the body's immune T-cells to attack cancer cells that carry a protein called KLK2. The main goals are to find the safest and most effec…

This study tests whether the drug apalutamide can delay prostate-specific antigen (PSA) progression in Chinese men with a type of prostate cancer that no longer responds to hormone therapy but hasn't spread. The trial involves 75 participants who receive either apalutamide or a p…

This early-phase study tests a new drug called JNJ-69086420 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug is an antibody linked to a radioactive particle that targets a protein found on prostate cancer cells. The st…

This study tests whether adding enzalutamide to standard hormone therapy and radiation can delay or prevent the spread of prostate cancer in men with high-risk localized disease. About 800 men will receive either standard treatment or standard treatment plus enzalutamide. The goa…

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants receive…

This study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy can help men with prostate cancer that has spread. About 1,145 men took part across 20 countries. The goal is to see if the combination delays cancer growth and improves surviva…

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug or a placebo alongside hormone therapy. The goal is…

This study tests a new imaging agent, 18F-DCFPyL, to see if it can better find prostate cancer that has spread in the body compared to a standard scan. About 96 adults with metastatic prostate cancer will receive both types of PET scans. The goal is to improve detection of cancer…

This study looks at whether taking marine omega-3 fatty acids (found in fish oil) and a drug called dutasteride can slow or prevent prostate cancer from getting worse in men with low-risk prostate cancer. The 120 participants are already on active surveillance, meaning they are c…

This study tests a personalized rehabilitation program designed to help men manage sexual side effects after prostate removal for cancer. About 135 men will either join the program or receive standard care. Researchers will compare their sexual quality of life one year after surg…

This study aimed to see if a 3-month supervised exercise program improves quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have received individual training with a physiotherapist. The study was withdrawn befo…

This study looks at whether a special MRI scan (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely avoid immediate treatment and just be monitored (active surveillance). About 200 men already on active surveillance will get the MRI. If the…

This study looks at how well different versions of two prostate cancer drugs, niraparib and abiraterone acetate, are absorbed by the body. About 136 men with advanced prostate cancer that no longer responds to hormone therapy will take part. The goal is to find which formulation …

This study collects blood or saliva samples from people with cancer and their relatives to build a DNA bank. Researchers will use these samples to study how genes may increase the risk of developing certain cancers. About 992 participants are expected. No treatment or direct bene…

This research study aims to identify specific prostate cancer markers in blood samples from 40 prostate cancer patients and 20 healthy volunteers. Researchers will test commercial antibodies to see which ones can detect these markers in circulating tumor cells. The goal is to imp…